Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Maze has two kidney disease drugs currently in the clinical, and the biotech was able raise $140 million in IPO cash to support those programs and more in its pipeline. Maze’s shares now trade ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

There were only 36 biotech IPOs last year, compared with 68 in 2015 and a record 85 in 2014 – and a rebound was expected in 2017. Are biotech IPOs back in fashion? | pharmaphorum Skip to main ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...